Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butenafine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butenafine SCHEMBL262301 | 1.00 | LMNA (0.97) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL676912 | 1.00 | LMNA (0.97) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL20456391 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL65526 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL29354083 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL1648813 | 0.96 | CYP2D6 (0.94) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL500751 | 0.91 | CYP2D6 (0.85) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL9314916 | 0.88 | LMNA (0.76) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9695182 | 0.87 | CYP2D6 (0.80) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9312678 | 0.86 | CYP2D6 (0.78) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| EP-3046762-B1 | ANTI-FOG FILMS AND PROCESSES FOR MAKING SAME | CELANESE ACETATE LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606694-B2 | Foamable cellulose acetate compositions, foams and foam articles formed therefrom | EASTMAN CHEMICAL COMPANY (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250382370-A1 | ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE | GENENTECH, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250352526-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12390971-B2 | Process and system for blending a plasticizer with a polysaccharide ester polymer | CELANESE INTERNATIONAL CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4591881-A2 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4331604-B9 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION | HOFFMANN LA ROCHE (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-12351654-B2 | Polymers, articles, and chemicals made from high concentrated recycle derived syngas | EASTMAN CHEMICAL COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| US-20220175743-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220169933-A1 | FEED LOCATION FOR GASIFICATION OF PLASTICS AND SOLID FOSSIL FUELS | EASTMAN CHEMICAL COMPANY (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022109228-A1 | CELLULOSE ESTER COMPOSITION AND ARTICLES MADE THEREFROM | CELANESE INTERNATIONAL CORPORATION (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162344-A1 | POLYMERS, ARTICLES, AND CHEMICALS MADE FROM HIGH CONCENTRATED RECYCLE DERIVED SYNGAS | EASTMAN CHEMICAL COMPANY (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162423-A1 | Cellulose Ester Composition and Articles Made Therefrom | ACETATE INTERNATIONAL LLC | 2022-05-26 | — | — | US | disclosed |
| US-11312914-B2 | Gasification of plastics and solid fossil fuels to produce organic compounds | EASTMAN CHEMICAL COMPANY (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114364731-A | Biodegradable products and method of production | RJ索尔特有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11286436-B2 | Feed location for gasification of plastics and solid fossil fuels | EASTMAN CHEMICAL COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2022059618-A1 | COAT-FORMING AEROSOL COMPOSITION AND AEROSOL TYPE COAT-FORMING TOPICAL FORMULATION | 久光製薬株式会社 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351654-B2 | Polymers, articles, and chemicals made from high concentrated recycle derived syngas | GYS1, CES2, GYS2 | SLC6A2 3757/4885SIGMAR1 2401/4885ADRA2A 2669/4885 |
| US-20220162344-A1 | POLYMERS, ARTICLES, AND CHEMICALS MADE FROM HIGH CONCENTRATED RECYCLE DERIVED SYNGAS | GYS1, CES2, GYS2 | SLC6A2 3757/4885SIGMAR1 2401/4885ADRA2A 2669/4885 |
| US-20220175743-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | PADI4, PIK3C3, PADI1 | SLC6A2 4377/4885SIGMAR1 4011/4885ADRA2A 4026/4885 |
| US-20250352526-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | PADI4, PIK3C3, PADI1 | SLC6A2 4377/4885SIGMAR1 4011/4885ADRA2A 4026/4885 |
| US-12606694-B2 | Foamable cellulose acetate compositions, foams and foam articles formed therefrom | FUS, TAF1, NSF | SLC6A2 1976/4885SIGMAR1 1258/4885ADRA2A 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.